Latest News Releases
Paris, France. 19 May 2022. We CARE, a joint initiative of PCR and Stent – Save a Life!, dedicated to restoring faith in cardiovascular healthcare and increasing awareness of the importance of timely and accessible treatment, is presenting a first study at EuroPCR 2022: a UK health economic analysis of the long-term health outcomes and cost for STEMIs during the COVID-19 UK lockdown.
New findings from the Ascension Health System’s internal National Cardiovascular Data Registry (NCDR) analyzing rates of percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) in parallel with COVID-19 surges is being presented today at the Society for Cardiovascular Angiography & Interventions (SCAI) 2022 Scientific Sessions. The findings reveal STEMI PCI cases dramatically dropped nearly 30% following the onset of the COVID-19 pandemic and have yet to recover to pre-pandemic levels.
- SCAI Scientific Sessions
Vaccines may help lessen long covid symptoms in some individuals, say researchers, but more data is needed before any firm conclusions can be drawn
- The BMJ
A COVID-19 booster shot will provide strong and broad antibody protection against the range of omicron sublineage variants of the SARS-CoV-2 virus in circulation, two new studies using serum from human blood samples suggest.
- New England Journal of Medicine
- National Institutes of Health, National Center for Advancing Translational Sciences, National Cancer Institute, Glenn Barber Fellowship from Ohio State’s College of Veterinary Medicine, Robert J. Anthony Fund for Cardiovascular Research
The multidisciplinary center will focus on development of antiviral drugs to combat coronaviruses and other viruses with pandemic potential
A consortium led by international scientists from the non-profit, open-science COVID Moonshot has been awarded an initial $68,662,387 from the US National Institutes of Health (NIH) to discover and develop globally accessible and affordable novel oral antivirals to combat COVID-19 and future pandemics.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded approximately $577 million to establish nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern.
- NIH/National Institute of Allergy and Infectious Diseases
New research finds that the novel coronavirus can make the mouse brain more susceptible to a toxin that induces nerve-cell loss seen in Parkinson’s.
- Movement Disorders
The rollout of remote teaching in New Jersey during the COVID-19 pandemic was haphazard, under-resourced, inequitably delivered, contributed to student and teacher stress and may exacerbate digital and social inequality, according to a Rutgers study.
- Journal of the Association for Information Science and Technology
Like storm waves battering a ship, new versions of the SARS-CoV-2 virus have buffeted the world one after another. Recently, scientists keeping tabs on these variants noticed a trend: Many carry the same set of three mutations. In a new study in ACS’ Biochemistry, researchers examined how these mutations change the way a key piece of the virus functions. Their experiments show how this triad alters traits it needs to cause and sustain COVID-19 infection.
Brensocatib did not improve the clinical status of patients hospitalized with severe SARS-CoV-2 infection in the double-blind randomized, placebo-controlled STOP-COVID19 multicenter clinical trial, according to research published at the ATS 2022 international conference.
- ATS 2022 International Conference
A study by Japanese researchers showed that getting a mild case of COVID-19 doesn’t translate to lower chances of becoming a long-hauler. And that sex and the presence of long-term symptoms are risk factors for post-COVID psychological distress.
- Scientific Reports
- Japan Agency for Medical Research and Development
Patients with severe COVID-19 who were given imatinib had lower mortality rates at 90-day follow-up, according to research published at the ATS 2022 international conference.
- ATS 2022 International Conference
In a new study detailing the immune response conferred by infection from different COVID-19 variants, scientists at Gladstone Institutes and UC San Francisco showed that the Omicron variant induces only a weak immune response. This means unvaccinated people who were infected with Omicron are only protected against future Omicron infections—but not against infections from other strains. For vaccinated people, however, an Omicron infection helped boost overall protection against many variants.
- NIH/National Institutes of Health, Natural Sciences and Engineering Research Council of Canada, Roddenberry Foundation, Howard Hughes Medical Institute, Emergent Ventures at the Mercatus Center, George Mason University, Innovative Genomics Institute, Centers for Disease Control and Prevention, Abbott Laboratories, Sandler Program for Breakthrough Biomedical Research at UCSF